Navigation Links
Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that the company's partner, Vical Incorporated, presented positive interim safety and tolerability data on 18 subjects from an ongoing Phase I clinical trial using Inovio's electroporation technology for intratumoral delivery into melanoma tumors of plasmid DNA (pDNA) encoding interleukin-2 (IL-2). The treatment demonstrated objective tumor responses in treated and untreated lesions. The data were presented at the annual meeting of the American Society of Clinical Oncology (Chicago, June 1-5) by Jon M. Richards, M.D., Ph.D., Lutheran General Hospital Division of Hematology/Oncology. Inovio's DNA delivery systems are designed to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.

The systemic delivery of high-dose recombinant IL-2 to treat melanoma is limited by significant toxicity. An alternative method for extended dosing of IL-2 that may reduce toxicity is by intratumoral injection (followed by electroporation to facilitate cellular uptake) of a plasmid DNA designed to produce IL-2 in the body. The primary objective of this ongoing Phase I pDNA IL-2/electroporation study is to evaluate the safety and tolerability of the latter approach in stage three and four metastatic melanoma patients. In the first stage of the trial, four treatment groups received escalating doses of 0.5, 1.5, 5 (mg per tumor), and 15 mg (5 mg in each of 3 tumors). In the ongoing second stage, patients are treated with the 15 mg dose.

The interim study results show that no serious adverse events related to the study drug or administration procedure have been reported and the treatment was well tolerated. The majority of related adverse events
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
Post Your Comments:
(Date:11/21/2014)... Clementia Pharmaceuticals, Inc.  announced ... has granted Orphan Medicinal Product Designation for ... the treatment of fibrodysplasia ossificans progressiva (FOP). ... disease characterized by painful, recurrent episodes of ... bone formation. This process, known as heterotopic ...
(Date:11/21/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced ... will be presenting at the 26 th Annual Piper ... New York . The formal presentation is ... In addition, Mr. Krakauer and Jorgen B. Hansen , ... during the day. An audio webcast will ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... 17, 2012  Eisai announced today that 15 abstracts highlighting new ... Annual Meeting of the American Society of Clinical Oncology (ASCO), ... 2012. These studies highlight Eisai,s current product ... and their families affected by cancer. "Our ...
... Janssen Pharmaceuticals, Inc. today announced the results ... ER (tapentadol) extended-release tablets were significantly more effective ... with chronic moderate to severe, painful diabetic peripheral ... at the 31st Annual Scientific Meeting of the ...
Cached Medicine Technology:Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 2Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 3Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 5Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 6Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 7Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 8Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 2Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 3Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 4Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 6Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 7Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 8Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 10Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 11Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 12
(Date:11/22/2014)... November 23, 2014 Today, Dylan Queen, ... new collection of wedding dresses; the business offers a ... related accessories for ladies worldwide, allowing them to create ... of the company, this new collection of chic wedding ... Moreover, they are offered at discounted rates now. Dylan ...
(Date:11/22/2014)... 22, 2014 Discount-Dress.com is an ... the firm is to increase the company’s online market share ... new selection of bridesmaid dresses and announced a bridesmaid dress ... valid until Dec. 30, 2014. All the dresses from this ... , In fact, Discount-Dress.com is very good at manufacturing ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 "My friend ... pain caused by the machine," said an inventor from ... had to go back a second time because the ... idea." , She developed the patent-pending MAMO EASY to ... cancer. The design saves the patient from the pain ...
(Date:11/22/2014)... The wide variety and complexity of foods served at ... food allergies, an expert warns. "Every person is ... allergies that it can be really difficult to avoid ... of allergy and clinical immunology at Wake Forest Baptist ... "If you know you have food allergies, caution should ...
(Date:11/22/2014)... This month has been a historical time for Angeldress.co.uk, ... positive reviews from some renowned review websites. Recently, the company ... a new selection of wonderful sexy wedding dresses to its ... shipping and up to an 80% discount on any order ... the most suitable dress at Angeldress.co.uk, which has garnered a ...
Breaking Medicine News(10 mins):Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2
... Together initiative, EAGAN, Minn., Dec. 6 ... recently awarded $1,151,700 in grants -- $810,000,under Growing ... Creating Community with New Americans, and $135,000 in ... effort, nurtures the healthy,growth and development of children ...
... is a,statement by Matthew L. Myers, President, Campaign ... in the December 5, 2007, issue of the ... including higher,tobacco taxes, smoke-free workplace laws, advertising bans ... and affordable strategies nations,can adopt to reduce deaths ...
... Experiments with rats show early exposure causes genetic changes ... -- A chemical found in many plastic products used ... in newborn female lab rats, a condition that might ... a new study says. , Butyl benzyl phthalate (BBP) ...
... 6, 2007 As in most fields of ... types of patients, through their individual genetic variations, ... combinations of drugs than other patients. A new ... investigated whether depressed patients with a particular genetic ...
... Mass., Dec. 6 Smith & Nephew,s,(NYSE: ... the launch of a,redesigned and expanded family of ... reduces fluid leakage and helps surgeons,manage sutures during ... through which surgeons insert,instruments during minimally invasive procedures., ...
... Training and Resources, WASHINGTON, Dec. 6 ... will provide nearly $4.7 million,for "caregiver assistance pilot ... provide needed training and resources for caregivers who,assist ... "This funding will enhance support and training for ...
Cached Medicine News:Health News:Blue Cross Foundation Invests in Community Health 2Health News:Blue Cross Foundation Invests in Community Health 3Health News:Blue Cross Foundation Invests in Community Health 4Health News:New Lancet Study: Tobacco Control Measures Are Effective and Affordable Strategies to Reduce Chronic Disease Deaths Globally 2Health News:New Lancet Study: Tobacco Control Measures Are Effective and Affordable Strategies to Reduce Chronic Disease Deaths Globally 3Health News:Common Household Chemical Could Raise Breast Cancer Risk 2Health News:Common Household Chemical Could Raise Breast Cancer Risk 3Health News:Possible genetic predictor for response to lithium augmentation in depressed patients 2Health News:Smith & Nephew Endoscopy Expands Line of CLEAR-TRAC(TM) Surgical Cannulas 2Health News:Smith & Nephew Endoscopy Expands Line of CLEAR-TRAC(TM) Surgical Cannulas 3Health News:VA Announces $4.7 Million to Help Caregivers 2Health News:VA Announces $4.7 Million to Help Caregivers 3
... reliable strength for temporary wound support. ... compliant and stretchable support material is ... is not required. Predictable absorption. Polyglactin ... inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... is designed for the repair of abdominal ... that has two distinct sides. One ... a layer of sodium hyaluronate and carboxymethylcellulose ... This coated side is bioresorbable, providing a ...
... Human explant studies have confirmed ... for maximum clinical performance in hernia ... Atriums thinner and less dense hernia ... less rigid repair. Since 1994, when ...
Medicine Products: